drugset / Trial / NCT00243347

The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer

NCT00243347

Phase 1 Completed 19 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is to examine the effects on tumors of AZD2171, in the treatment of NSCLC or HNC. The safety and tolerability of AZD2171 will also be studied.

Timeline

Start
2005-12
Primary completion
2008-05
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cediranib Small molecule Oral